Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2010) 24 OC4.2

BSPED2010 Oral Communications Oral Communications 4 (Brief Communications) (4 abstracts)

Medium term impact of continuous subcutaneous insulin infusion (CSII) on HbA1c levels: A regional meta-analysis of 185 patients

A Sinha 1 , A Butt 2 , N Hopper 2 , T Mukundan 3 , E Posner 3 , J Jani 6 , F Jamil 4 , J Ahmed 6 , A Norrington 7 , M Burns 7 , G Birrell 7 , B Lamb 5 & T Cheetham 1


1Great North Children’s Hospital, Newcastle upon Tyne, UK; 2Sunderland Royal Hospital, Sunderland, UK; 3University Hospital of North Durham, Durham, UK; 4Darlington Memorial Hospital, Darlington, UK; 5Bishop Auckland Hospital, Bishop Auckland, UK; 6University Hospital of Hartlepool, Hartlepool, UK; 7James Cook University Hospital, Middlesbrough, UK.


Background: The use of CSII in children with T1DM is increasing. Several meta-analyses have concluded that there is an improvement in glycaemic control with CSII but most of these investigations have included adults and have been of short duration (<6 months). Our aim was to assess the medium term impact of CSII on HbA1c levels in patients managed with CSII in one region of The UK.

Methods: Data was collected retrospectively from 7 centres within North-East England. These centres manage the majority of young people on CSII (>95%) in the locality. Only patients under the age of 18 who had been on insulin injections for 1 year prior and at least 1 year of CSII therapy were included. HbA1c data pre and post CSII initiation was collected and then analysed using meta-analysis software (Review Manager 5.0) and Minitab v15.0. Results are expressed as mean differences, calculated from end of treatment values, with 95% confidence intervals (CI) for continuous outcomes. Pooled results were meta-analysed using the generic inverse variance method with a fixed-effects model. Statistical significance was set at a P value ≤0.05.

Results: Data from 185 patients was included in the meta-analysis. There was a significant improvement in HbA1c favouring CSII therapy at 4 months post CSII initiation (P=0.05, weighted mean difference −0.23; 95% confidence intervals −0.47, 0.00) but this trend was not sustained at 1 year (P=0.88, weighted mean difference −0.02; 95% confidence intervals −0.30, 0.26) or 2 years (P=0.27, weighted mean difference 0.19; 95% confidence intervals −0.14, 0.51).

Conclusions: The impact of CSII in isolation is remarkably similar to many other initiatives involving new insulin regimens in T1DM with a short term improvement in HbA1c that wanes in the longer term.

Volume 24

38th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.